NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 230 filers reported holding NEKTAR THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $13,859 | -96.8% | 24,095 | -96.1% | 0.00% | -100.0% |
Q1 2023 | $432,211 | -55.7% | 614,897 | +42.4% | 0.01% | -56.7% |
Q4 2022 | $976,087 | -5.9% | 431,897 | +33.2% | 0.03% | -26.8% |
Q3 2022 | $1,037,000 | +6.8% | 324,356 | +26.8% | 0.04% | +5.1% |
Q2 2022 | $971,000 | +61.3% | 255,771 | +128.7% | 0.04% | +85.7% |
Q1 2022 | $602,000 | – | 111,823 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
CM Management, LLC | 50,000 | $858,000 | 0.62% |
Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |